{"description":"The level of key regulators of the MEK/MAPK and PI3K pathways and HSP90 and cell cycle regulators may determine the anti-tumor response to AZD6244 in vivo in multiple myeloma (MM).","reportingStatus":"NOT_POSTED","timeFrame":"Up to 20-30 hours after receiving the first dose of selumetinib","title":"Level of Key Regulators","type":"OTHER_PRE_SPECIFIED"}